Mr. Kaushal is a finance and life sciences industry executive with over 25 years of experience in financial investing, healthcare services, medical devices, and capital markets.

Mr. Kaushal is the President of Anik Capital Corp., a family holding company, and serves as Executive Chairman of Hyasynth Biologicals, Inc. He currently holds board positions at several publicly traded and private companies, including Delta 9 Cannabis Inc. (Chairman since May 2021), Viemed Healthcare, Inc. (Director since November 2017), High Tide Inc. (Director since October 2018), and Everyday People Financial Corp.

Previously, Mr. Kaushal was the Managing Director in the Corporate Finance practice at PwC Canada, a role he held until his retirement in March 2020. Over his career, he has held senior leadership positions in investment banking, venture capital, and consulting firms and has served on the boards of multiple pharmaceutical and healthcare companies.

Mr. Kaushal has advised on over 50 mergers, acquisitions, and strategic transactions and has worked with global pharmaceutical companies on licensing and regulatory strategies. He has also been involved in capital market transactions, raising over $2 billion in financing.

Mr. Kaushal holds a Bachelor of Science in Chemistry from the University of Toronto and is a Chartered Accountant (CPA, CA) in Canada.

Dr. Madhok is a biotechnology executive and strategic advisor. He will contribute extensive experience in corporate strategy, business development, and transaction advisory in the pharmaceutical and biotech industries to the board of directors.

Dr. Madhok is the Founder of Novalio Pharma, a biotech strategic advisory firm (2021-present), and currently serves as Chief Business Officer of Cytoki Pharma, a biotechnology company focused on metabolic diseases (2021-present). Previously, he was Chief Executive Officer of Zarodex Therapeutics (2020-2021), an immunology-focused biotechnology company, Chief Business Officer of Topivert Pharma (2018-2020), specializing in ophthalmology, Vice President of Business Development at Jazz Pharmaceuticals (2012-2018) and Vice President of Corporate Development at EUSA Pharma, where he was responsible for the $700 million sale of EUSA Pharma to Jazz Pharmaceuticals in 2012.

During his tenure at Jazz Pharmaceuticals, Dr. Madhok originated and led key strategic transactions, including the $1 billion acquisition of Gentium in 2014. In addition to his M&A, business development and strategic advisory experience, he has also been involved in commercial operations, including the U.S. launch of a hematology-oncology drug.

Prior to his career in pharmaceutical and biotechnology industries, Dr. Madhok held roles in healthcare investment banking at HSBC and J.P. Morgan and worked in equity research at Bear Stearns (2003-2009).

Dr. Madhok holds a Ph.D. in Chemical Engineering from the University of Cambridge, UK, and a B.Sc. in Chemistry from the University of Copenhagen, Denmark.

Dr. Geraghty is a seasoned life sciences executive with over 20 years of experience encompassing corporate strategy, portfolio management, commercialization, and finance within the biotechnology and pharmaceutical sectors.

In February 2021, Dr. Geraghty was appointed as the President and Chief Executive Officer of Anokion SA, a Swiss biotechnology company focused on treating autoimmune diseases by restoring normal immune tolerance. Prior to this role, she served as the company’s Chief Operating Officer and Chief Business Officer, bringing extensive experience in the life sciences industry.

Before joining Anokion, Dr. Geraghty held the position of Senior Vice President of Corporate Strategy at Dimension Therapeutics, where she played a pivotal role in the company’s private and public financing efforts, portfolio strategy and growth, and facilitated the acquisition by Ultragenyx Pharmaceutical Inc. She also co-founded and served as Vice President of Project and Portfolio Development at Cydan Development, an orphan drug accelerator. Earlier in her career, Dr. Geraghty held leadership roles at Aileron Therapeutics as Head of Portfolio Advancement and at Infinity Pharmaceuticals as Director of New Product Marketing. She was also a founder of Back Bay Strategies and held positions at Kendall Strategies, Feinstein Kean Healthcare, and Genzyme Corp.

Dr. Geraghty currently serves on the Board of Directors of ReAlta Life Sciences, Inc., where she chairs the audit committee, and is a board member of the Medical University of South Carolina (MUSC) Foundation for Research Development (FRD), the university’s technology transfer office.

She earned a B.S. in Biology from Union College, an M.B.A. from the Carroll School at Boston College, and a Ph.D. in Molecular Biology from the University of Vermont.